November 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOMOB (Mobocertinib 40mg) capsules for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutation. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.Mobocertinib is an irreversible kinase inhibitor, forming a covalent…
October 06, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIODEUCRA (Deucravacitinib 6mg) tablets for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the first approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis…
October 05, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOPALB (Palbociclib 125mg) capsules are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or fulvestrant in patients…
September 20, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Bioscovy (emtricitabine 200mg/ tenofovir alafenamide 25mg) tablet for customers, each box of Bioscovy includes 30 tablets. It is a tablet taken by mouth. Bioscovy for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. Bioscovy for PrEP is not for everyone: It is not…
